All 13 CNS germinoma patients remained event-free at five years after upfront RT, but treatment-sequencing comparisons in nongerminomatous tumors remain inconclusive.
Across 32 years of T1 anal cancer treatment, five-year colostomy-free survival reached 85.3%, with no treatment-related colostomies.
In 331 Danish NPC patients, five-year failure rates were similar by EBV status, while distant relapse was concentrated in locally advanced disease.
Treatment discontinuation was 25.0% with pre-RT cachexia versus 4.6% without, with approximately sixfold higher adjusted odds.
After propensity matching, overall survival was similar between surgery plus adjuvant RT and definitive RT, while disease-control differences remained non-significant.
Radical radiotherapy use nearly doubled while five-year lung cancer-specific survival rose from 21.9% to 33.1% across Northern Ireland.